Even well-studied proteins can reveal surprises. University of Iowa scientists have discovered a new enzyme activity for the cystic fibrosis transmembrane conductance regulator (CFTR). CFTR is the ...

The cystic fibrosis transmembrane conductance regulator has been studied for years but the new efforts have yielded important insights. Scientists at St. Jude Children's Research Hospital and ...

Scientists at St. Jude Children's Research Hospital and Rockefeller University have combined their expertise to gain a better understanding of the cystic fibrosis transmembrane conductance regulator ...

Protein folding diseases, from Alzheimer's to Gaucher's, may one day be treated by a unique class of protein corrector molecules that are already helping manage cystic fibrosis. Protein misfolding is ...

A UB-led research team has developed molecules that could help unclog thick, sticky mucus from the lungs of people suffering from cystic fibrosis. The chronic disease is caused by a defective protein ...

Protein misfolding is a likely culprit in many degenerative disorders. Cystic fibrosis, for instance, is caused by mutations in the CFTR gene that prevent the eponymous protein from assuming its ...

Fluorescence microscope image of cells in the lung’s blood vessels. The study has shown for the first time that these cells possess a CFTR chloride channel (green), and that lung inflammation-induced ...

Sionna Therapeutics, Inc. announced that preclinical data on its novel cystic fibrosis (CF) treatment candidates, SION-451 and SION-719, will be presented at the European Cystic Fibrosis Society’s ...

BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that five scientific abstracts on the company’s portfolio of cystic fibrosis (CF) medicines will be ...